Goldman Sachs
BCDA icon

Goldman Sachs’s BioCardia BCDA Stock Holding History

Goldman Sachs’s Portfolio BCDA Stock Details BCDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,378
Closed -$71K – 5211
2019
Q3 		$71K Buy
+1,378
New +$98.9K ﹤0.01% 5003

Other funds holding BCDA

LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Goldman Sachs's BCDA Position: Q4 2019 in Review

Goldman Sachs sold out of BioCardia (BCDA) in Q4 2019, closing a stake of 1,378 shares — an estimated $71K sold.

Goldman Sachs first reported a position in BCDA in Q3 2019 and held it in 1 quarter. The position peaked at $71K in Q3 2019. 8 funds tracked by Wall St. Rank hold BCDA as of Q4 2019.

  • Goldman Sachs reported no remaining BioCardia position as of Q4 2019 after selling out during the quarter.
  • Goldman Sachs sold 1,378 BioCardia shares in Q4 2019, an estimated $71K.
  • Goldman Sachs first reported a position in BioCardia in Q3 2019 and held it in 1 quarter.
  • Goldman Sachs's BioCardia position peaked at $71K in Q3 2019.
  • 8 funds tracked by Wall St. Rank held BioCardia as of Q4 2019.

Based on Goldman Sachs's 13F filing for Q4 2019, filed 14 Feb 2020.